Sharon has been intrigued by our drug even with the top line results last May. She wasn't quick to judge as some have been. Looking at the blood bath BIIB is taking after hours now that its been found out that early on their latest drug performed even worse than placebo (making it much more difficult to predict positive performance moving forward), it would seem that we are one of the last standing with a legit run trial and stat significant efficacy results in any population. JMHO
News 
Market Data 
Discover 
